DOCSLIB.ORG

Downloaded From

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Downloaded From Kent Academic Repository Full text document (pdf) Citation for published version BORE, Joseph Akoi (2020) Sero-prevalence of Ebola and Lassa virus in the Republic of Guinea, Macenta prefecture. Doctor of Philosophy (PhD) thesis, University of Kent, Public Health England (PHE), Porton. DOI Link to record in KAR https://kar.kent.ac.uk/82364/ Document Version UNSPECIFIED Copyright & reuse Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder. Versions of research The version in the Kent Academic Repository may differ from the final published version. Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the published version of record. Enquiries For any further enquiries regarding the licence status of this document, please contact: [email protected] If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at http://kar.kent.ac.uk/contact.html University of Kent School of Biosciences Sero-prevalence of Ebola and Lassa virus in the Republic of Guinea, Macenta Prefecture. by Joseph Akoi BORE Thesis for the degree of Doctor of Philosophy June 2020 1 Abstract Following the 2013–2016 West Africa Ebolavirus (EBOV) outbreak, a broad range of scientific research has been conducted to understand and prevent future epidemics. Our current study, supported by the United States Food and Drug Administration (FDA), uses sero-epidemiology to look at the footprint in- cidence of EBOV and Lassa virus (LASV) in the prefecture of Macenta located in forested Guinea. Our study assesses seroprevalence of these zoonotic vi- ruses in bushmeat hunters and their household members. These groups of people are at risk of exposure to multiple viral zoonotic infections via constant contact with wildlife, either by hunting, trapping or butchering. In order to in- vestigate potential historical EBOV and/or Lassa virus LASV infections, serum samples were collected from villages that were affected or unaffected by the 2013-2016 EBOV outbreak in Guinea. We performed Enzyme-Linked Im- munosorbent Assay (ELISA), western blot analysis and flow cytometry for the detection of EBOV glycoprotein (GP) and LASV nucleoprotein (NP) antigens specific immunoglobulin G. A number of positive samples were detected for both pathogens, suggesting that these two pathogens are circulating in Guinea and may cause mild or asymptomatic infection in a proportion of cases. Im- portantly, this study suggests EBOV may have been circulating in Guinea be- fore the 2013-2016 outbreak. 2 Hypothesis of the Thesis The primary purpose of this study is to assess to what extent Ebolavirus has been circulating within the forested region of Guinea prior to the 2013-2016 Ebola virus disease (EVD) outbreak in West Africa. Due to the nature of their work, bushmeat hunters and their household family members are deemed to be at high risk of Ebo- lavirus contamination and spill over. We then established a cohort of bushmeat hunt- ers and their immediate families and collected serum samples from volunteers. We looked for the presence of anti-Ebolavirus antibodies to determine previous exposure to the virus. Our cohort includes bushmeat hunters from villages affected by the 2013- 16 Ebolavirus outbreak and villages that were not affected. Therefore, we hypothe- sized that a number of samples from previously non exposed villages to EVD will contain anti-Ebolavirus antibodies, suggesting that the virus has been circulating or still circulate in the zone prior to the past Ebola virus outbreak. 3 Table of Contents Abbreviation list .................................................................................................................. 7 List of Tables ........................................................................................................................ 9 List of Figures .................................................................................................................... 10 Acknowledgements .......................................................................................................... 11 Publication .......................................................................................................................... 12 DECLARATION OF AUTHORSHIP ................................................................................ 13 GENERAL INTRODUCTION .............................................................................. 14 1.1 Ebola virus .................................................................................................................. 15 1.1.1 Discovery of Ebola virus ..................................................................................... 15 1.1.2 Notable historical outbreaks .............................................................................. 16 1.1.3 Ebola; Species and phylogenetics ...................................................................... 20 1.1.4 Ebola; Genome structure and organization ....................................................... 21 1.1.5 Ebola; Replication .............................................................................................. 22 1.1.6 Ebola; Disease and immune response ............................................................... 23 1.1.6.1 Innate immune response to Ebola virus ........................................................ 24 1.1.6.2 Adaptive response to Ebola virus ................................................................... 25 1.1.6.3 B cells responses to Ebola virus ..................................................................... 25 1.1.6.4 T cells responses to Ebola virus...................................................................... 26 1.1.6.5 B and T cells dynamics ................................................................................... 27 1.1.7 Host immune response and outcome to survival .............................................. 28 1.1.8 Ebola; Reservoir and Transmission .................................................................... 31 1.1.8.1 Transmission .................................................................................................. 34 1.1.9 Age factor in Ebola virus infection outcome ...................................................... 35 1.1.10 Co-infection and clinical outcome of EVD .......................................................... 35 1.1.11 Ebola; Diagnosis, prophylaxis and vaccines ....................................................... 36 1.2 The West African EVD Outbreak of 2013-2016 ......................................................... 37 1.2.1 West African Outbreak management ................................................................ 40 1.2.2 Social impact of the West Africa EVD ................................................................ 41 1.3 Sub symptomatic infections ....................................................................................... 42 1.3.1 Potential reason for sub -symptomatic infection .............................................. 43 1.3.2 Historical Filovirus sub symptomatic infection .................................................. 43 1.3.3 Case studies on Ebola virus asymptomatic transmission .................................. 45 1.3.4 Pros and cons of seroprevalence studies ........................................................... 48 1.4 Lassa virus; Introduction ............................................................................................ 49 1.4.1 Discovery of Lassa virus ..................................................................................... 50 1.4.2 Lassa; Species and Phylogeny ............................................................................ 51 1.4.3 Lassa; Genome structure and organization ....................................................... 51 4 1.4.4 Lassa; Replication ............................................................................................... 53 1.4.5 Lassa; Transmission ............................................................................................ 55 1.4.6 Lassa; Immune response .................................................................................... 57 1.4.7 Lassa; Clinical symptoms and treatment ........................................................... 58 1.5 Study aim and objectives ........................................................................................... 60 MATERIALS AND METHODS ........................................................................... 61 2.1 Sample collection ....................................................................................................... 62 2.2 Enzyme-Linked Immunosorbent Assays (ELISA) ........................................................ 62 2.2.1 Indirect ELISA assay procedure .......................................................................... 62 2.2.2 Ebola virus Glycoprotein detection .................................................................... 64 2.2.3 Lassa virus IgG detection.................................................................................... 66 2.2.4 Lassa virus IgG detection ELISA assay procedure............................................... 67 2.3 Ebola virus protein detection by western blot .........................................................
Load more

Recommended publications
  • Ebola Virus Disease
    Outbreaks Chronology: Ebola Virus Disease Known Cases and Outbreaks of Ebola Virus Disease, in Reverse Chronological Order: Reported number (%) of Reported deaths Ebola number of among Year(s) Country subtype human cases cases Situation August- Democratic Ebola virus 66 49 (74%) Outbreak occurred in November 2014 Republic of multiple villages in the Congo the Democratic Republic of the Congo. The outbreak was unrelated to the outbreak of Ebola in West Africa. March 2014- Multiple Ebola virus 28652 11325 Outbreak across Present countries multiple countries in West Africa. Number of patients is constantly evolving due to the ongoing investigation. 32 November 2012- Uganda Sudan virus 6* 3* (50%) Outbreak occurred in January 2013 the Luwero District. CDC assisted the Ministry of Health in the epidemiologic and diagnostic aspects of the outbreak. Testing of samples by CDC's Viral Special Pathogens Branch occurred at UVRI in Entebbe. 31 June-November Democratic Bundibugyo 36* 13* (36.1%) Outbreak occurred in 2012 Republic of virus DRC’s Province the Congo Orientale. Laboratory support was provided through CDC and the Public Health Agency of Canada (PHAC)’s field laboratory in Isiro, as well as through the CDC/UVRI lab in Uganda. The outbreak in DRC had no epidemiologic link to the near contemporaneous Ebola outbreak in the Kibaale district of Uganda. 31 June-October Uganda Sudan virus 11* 4* (36.4%) Outbreak occurred in 2012 the Kibaale District of Uganda. Laboratory tests of blood samples were conducted by the UVRI and the CDC. 31 May 2011 Uganda Sudan virus 1 1 (100%) The Uganda Ministry of Health informed the public a patient with suspected Ebola Hemorrhagic fever died on May 6, 2011 in the Luwero district, Uganda.
    [Show full text]
  • Replication of Marburg Virus in Human Endothelial Cells a Possible Mechanism for the Development of Viral Hemorrhagic Disease
    Replication of Marburg Virus in Human Endothelial Cells A Possible Mechanism for the Development of Viral Hemorrhagic Disease Hans-Joachim Schnittler,$ Friederike Mahner, * Detlev Drenckhahn, * Hans-Dieter Klenk, * and Heinz Feldmann * *Institut fir Virologie, Philipps-Universitdt Marburg, 3550 Marburg, Germany; tInstitutftirAnatomie, Universitdt Wiirzburg, 8700 Wiirzburg, Germany Abstract Rhabdoviridae, within the new proposed order Mononegavi- Marburg and Ebola virus, members of the family Filoviridae, rales (10). Virions are composed of a helical nucleocapsid cause a severe hemorrhagic disease in humans and primates. surrounded by a lipid envelope. The genome is nonsegmented, The disease is characterized as a pantropic virus infection often of negative sense, and 19 kb in length (3, 11, 12). Virion parti- resulting in a fulminating shock associated with hemorrhage, cles contain at least seven structural proteins (8, 13-16). and death. All known histological and pathophysiological pa- Filovirus infections have several pathological features in rameters of the disease are not sufficient to explain the devas- common with other severe viral hemorrhagic fevers such as tating symptoms. Previous studies suggested a nonspecific de- Lassa fever, hemorrhagic fever with renal syndrome, and struction of the endothelium as a possible mechanism. Con- Dengue hemorrhagic fever (5). Among these viruses, filovi- cerning the important regulatory functions of the endothelium ruses cause the highest case-fatality rates ( - 35% for MBG [61 (blood pressure, antithrombogenicity, homeostasis), we exam- and up to 90% for EBO, subtype Zaire [17]) and the most ined Marburg virus replication in primary cultures of human severe hemorrhagic manifestations. The pathophysiologic endothelial cells and organ cultures of human umbilical cord events that make filovirus infections of humans so devastating veins.
    [Show full text]
  • Comparison and Evaluation of Real-Time Taqman PCR for Detection and Quantification of Ebolavirus
    viruses Article Comparison and Evaluation of Real-Time Taqman PCR for Detection and Quantification of Ebolavirus Yi Huang 1,* , Shuqi Xiao 2 and Zhiming Yuan 1,* 1 National Biosafety Laboratory, Chinese Academy of Sciences, Wuhan 430020, China 2 Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430020, China; [email protected] * Correspondence: [email protected] (Y.H.); [email protected] (Z.Y.) Abstract: Given that ebolavirus causes severe and frequently lethal disease, its rapid and accurate detection using available and validated methods is essential for controlling infection. Real-time reverse-transcription PCR (RT-PCR) has proven to be an invaluable tool for ebolaviruses diagnostics. Many assays with different targets have been developed, but they have not been externally compared or validated, and limits of detection are not uniformly reported. Here we compared and evaluated the sensitivity, reproducibility and specificity of 23 in-house assays under the same conditions. Our results showed that these assays were highly gene- and species- specific when evaluated using in vitro RNA transcripts and viral RNA, and the potential limits of detection were uniformly reported 2 6 ranging from 10 to 10 in vitro synthesized RNA transcripts copies perµL and 1–100 TCID50/mL. The comparison of these assays indicated that those targeting the more conservative NP gene could be the better option for EVD case definition and quantitative measurement because of its higher sensitivity for the same species. Our analysis could contribute to the standardization of ebolavirus detection and quantification assays, which can offer a better understanding of the meaning of results across laboratories and time points, as well as make them easy to implement, especially under outbreak conditions.
    [Show full text]
  • Guinea Ebola Response International Organization for Migration
    GUINEA EBOLA RESPONSE INTERNATIONAL ORGANIZATION FOR MIGRATION SITUATION REPORT From 9 to 31 May, 2016 First simulation exercise to manage EVD cases at the Point of Entry of Madina Oula, at the border with Sierra Leone. News © IOM Guinea 2016 Between May 9 and 13, IOM, in partnership with On the 12 May, IOM organized a On the 14 May, in partnership with CDC, launched the first simulation exercise to manage groundbreaking ceremony at the Tamaransy International Medical Corps (IMC), IOM EVD cases at the Madina Oula Point of Entry (PoE), at market, a village in Boké Prefecture that was officially launched Community Event-Based the border with Sierra Leone. Between May 22 and heavily affected by EVD. This activity is part of Surveillance (CEBS) in the prefecture of 26, it launched the second simulation exercise at the IOM’s support to the Guinean Government in Kindia. Many prefectural health and PoE of Baala, near Liberia. The main objective of these the socio-economic recovery of Ebola administrative authorities participated in the exercises is to prepare the authorities in charge of the Survivors. ceremony, during which bicycles and two points of entry in detecting, notifying and managing motorcycles were distributed to community any suspected case of potential epidemic disease, health agents and their supervisors. especially EVD cases at their various borders. Epidemiological situation On 29 March 2016, the World Health Organization (WHO) declared the end of EVD in West Africa as a Public Health Emergency of International Concern. In its situation report of 26 May 2016, WHO underlined that the latest notified case in Guinea during the resurgence of Ebola in mid-March was declared Ebola negative for the second time in a row after final testing on 19 April, 2016.
    [Show full text]
  • Biomarker Correlates of Survival in Pediatric Patients with Ebola Virus Disease
    Emerging Infectious Diseases. Volume 20, Number 10—October 2014 CDC EID journal Ahead of Print / In Press Research Biomarker Correlates of Survival in Pediatric Patients with Ebola Virus Disease Anita K. McElroy , Bobbie R. Erickson, Timothy D. Flietstra, Pierre E. Rollin, Stuart T. Nichol, Jonathan S. Towner, and Christina F. Spiropoulou Author affiliations: Emory University, Atlanta, Georgia, USA (A.K. McElroy); Centers for Disease Control and Prevention, Atlanta (A.K. McElroy, B.R. Erickson, T.D. Flietstra, P.E. Rollin, S.T. Nichol, J.S. Towner, C.F. Spiropoulou) Suggested citation for this article Abstract Outbreaks of Ebola virus disease (EVD) occur sporadically in Africa and are associated with high case-fatality rates. Historically, children have been less affected than adults. The 2000–2001 Sudan virus–associated EVD outbreak in the Gulu district of Uganda resulted in 55 pediatric and 161 adult laboratory-confirmed cases. We used a series of multiplex assays to measure the concentrations of 55 serum analytes in specimens from patients from that outbreak to identify biomarkers specific to pediatric disease. Pediatric patients who survived had higher levels of the chemokine regulated on activation, normal T-cell expressed and secreted marker and lower levels of plasminogen activator inhibitor 1, soluble intracellular adhesion molecule, and soluble vascular cell adhesion molecule than did pediatric patients who died. Adult patients had similar levels of these analytes regardless of outcome. Our findings suggest that children with EVD may benefit from different treatment regimens than those for adults. Outbreaks of Ebola virus disease (EVD) occur sporadically in sub-Saharan Africa and are associated with exceptionally high case-fatality rates (CFRs).
    [Show full text]
  • To Ebola Reston
    WHO/HSE/EPR/2009.2 WHO experts consultation on Ebola Reston pathogenicity in humans Geneva, Switzerland 1 April 2009 EPIDEMIC AND PANDEMIC ALERT AND RESPONSE WHO experts consultation on Ebola Reston pathogenicity in humans Geneva, Switzerland 1 April 2009 © World Health Organization 2009 All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distin- guished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.
    [Show full text]
  • Understanding Ebola
    Understanding Ebola With the arrival of Ebola in the United States, it's very easy to develop fears that the outbreak that has occurred in Africa will suddenly take shape in your state and local community. It's important to remember that unless you come in direct contact with someone who is infected with the disease, you and your family will remain safe. State and government agencies have been making preparations to address isolated cases of infection and stop the spread of the disease as soon as it has been positively identified. Every day, the Centers of Disease Control and Prevention (CDC) is monitoring developments, testing for suspected cases and safeguarding our lives with updates on events and the distribution of educational resources. Learning more about Ebola and understanding how it's contracted and spread will help you put aside irrational concerns and control any fears you might have about Ebola severely impacting your life. Use the resources below to help keep yourself calm and focused during this unfortunate time. Ebola Hemorrhagic Fever Ebola hemorrhagic fever (Ebola HF) is one of numerous Viral Hemorrhagic Fevers. It is a severe, often fatal disease in humans and nonhuman primates (such as monkeys, gorillas, and chimpanzees). Ebola HF is caused by infection with a virus of the family Filoviridae, genus Ebolavirus. When infection occurs, symptoms usually begin abruptly. The first Ebolavirus species was discovered in 1976 in what is now the Democratic Republic of the Congo near the Ebola River. Since then, outbreaks have appeared sporadically. There are five identified subspecies of Ebolavirus.
    [Show full text]
  • Biogas Potential Assessment of Animal Waste in Macenta Prefecture (Republic of Guinea)
    Vol-4 Issue-5 2018 IJARIIE-ISSN(O)-2395-4396 Biogas potential assessment of animal waste in Macenta prefecture (Republic of Guinea) Ansoumane SAKOUVOGUI1, Mamadou Foula BARRY1, Mamby KEITA2, Saa Poindo TONGUINO4 [email protected], [email protected], [email protected], [email protected] 1,2 Higher Institute of Technology of Mamou - Guinea 3Department of Physics, Gamal Abdel Nasser University of Conakry - Guinea 4Higher Institute Agronomic of Faranah - Guinea ABSTRACT This study focuses on the evaluation of the biogas potential of animal wastes in Macenta Prefecture. The census of the three types of herds living in 14 sub-prefectures and the urban commune of Macenta was carried out, of which: 13386 cattles, 17418 pigs and 20005 laying hens. The assessment of daily waste by type of animal was made .The results were 4.23 kg/day of dung per cow; 2.41 kg/d and 2.21 kg/d of pig slurry respectively in semi- improved and local breeding; 0.013 kg/day of droppings per hen. These values made possible to estimate the daily quantities of waste by type of livestock: cow dung (56622.78 kg), pig manure (40967.38 kg) and chicken manure (260.065 kg). The total daily biogas potential of the waste is therefor of the order of 8969.606 m3, distributed as follows: 6164.427 m3 for cow dung; 2332.117 m3 for pig manure and 473.063 m3 for chicken manure. This potential is distributed by locality and livestock types. Keywords: Evaluation, Potential, Biogas, Waste, Animal. 1. Introduction Biogas is a colorless and flammable gas produced by anaerobic digestion of animal, plant, human, industrial and municipal waste.
    [Show full text]
  • Zika: the Emerging Epidemic
    Contents 1 : T H E DOENÇA MISTERIOSA 2 : T H E O R I G I N S O F T H E V I R U S 3 : O N T H E M O V E 4 : T H E W O R L D H E A R S 5 : M Y F I R S T B R U S H 6 : FA S T A N D F U R I O U S 7 : S E X U A L T R A N S M I S S I O N 8 : N E W Y O R K ’ S F I R S T C A S E 9 : T H E R U M O R S 10: T H E P R O O F 11: D E L AY I N G P R E G N A N C Y 12: T H E F U T U R E 13: Q U E S T I O N S A N D A N S W E R S N O T E S Estimated range of Aedes albopictus and Aedes aegypti in the United States, 2016. Redrawn from a map from the Centers for Disease Control and Prevention. Countries, territories, and areas showing the distribution of Zika virus, 2013–2016. Redrawn from map printed in WHO, “Situation Report: Zika Virus, Microcephaly, and Guillain-Barré Syndrome,” May 26, 2016, p. 4, http://www.who.int/emergencies/zika-virus/situation- report/en/. © 2016 by World Health Organization. ZIKA 1 The Doença Misteriosa I N A U G U S T 2 0 1 5 , something strange began happening in the maternity wards of Recife, a seaside city perched on the northeastern tip of Brazil where it juts out into the Atlantic.
    [Show full text]
  • Temporal and Spatial Limitations in Global Surveillance for Bat Filoviruses and Henipaviruses: Online Appendix Daniel J. Becker
    Temporal and spatial limitations in global surveillance for bat filoviruses and henipaviruses: Online Appendix Daniel J. Becker, Daniel E. Crowley, Alex D. Washburne, Raina K. Plowright S1. Systematic search S2. Full reference list S3. Bat phylogeny S4. Post-hoc sampling design analysis S1. Systematic search Figure S1. The data collection and inclusion process for studies of wild bat filovirus and henipavirus prevalence and seroprevalence (PRISMA diagram). Searches used the following string: (bat* OR Chiroptera*) AND (filovirus OR henipavirus OR "Hendra virus" OR "Nipah virus" OR "Ebola virus" OR "Marburg virus" OR ebolavirus OR marburgvirus). Searches were run during October 2017. Publications were excluded if they did not assess filovirus or henipavirus prevalence or seroprevalence in wild bats or were in languages other than English. Records identified with Web of Science, CAB Abstracts, and PubMed (n = 1275) Identification Records after duplicates removed (n = 995) Screening Records screened Records excluded (n = 995) (n = 679) Full-text articles excluded for Full-text articles irrelevance, bats in assessed for eligibility captivity, other bat (n = 316) virus, not filovirus or henipavirus prevalence or Eligibility seroprevalence, not virus in bats (n = 260) Studies included in qualitative synthesis (n = 56) Studies included in Included quantitative synthesis (n = 56; n = 48 for the phylogenetic meta- analysis) S2. Full reference list 1. Amman, Brian R., et al. "Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection." PLoS Pathogens 8.10 (2012): e1002877. 2. de Araujo, Jansen, et al. "Antibodies against Henipa-like viruses in Brazilian bats." Vector- Borne and Zoonotic Diseases 17.4 (2017): 271-274.
    [Show full text]
  • West Africa – Ebola Outbreak Fact Sheet #23, Fiscal Year (Fy) 2015 March 4, 2015
    WEST AFRICA – EBOLA OUTBREAK FACT SHEET #23, FISCAL YEAR (FY) 2015 MARCH 4, 2015 NUMBERS AT HIGHLIGHTS USG HUMANITARIAN ASSISTANCE A GLANCE TO EVD OUTBREAK RESPONSE WHO reports 132 new confirmed cases of TO DATE IN FY 2014 & FY 2015 EVD in Guinea and Sierra Leone in the 23,934 week ending on March 1. USAID/OFDA1 $463,846,949 No new EVD cases confirmed in Liberia USAID/FFP2 $57,479,546 Number of Suspected, in nearly two weeks. Probable, and Confirmed USAID/GH3 $20,076,000 Ebola Virus Disease (EVD) Response actors remain concerned Cases in Acutely Affected regarding ongoing EVD transmission USAID/Liberia $16,100,000 Countries* chains in Guinea’s Forécariah Prefecture, USAID/Guinea $3,482,000 UN World Health Organization where 23 EVD cases since February 28— (WHO) – DoD4 $353,958,000 March 4, 2015 more than 70 percent of the 32 confirmed cases in the same time period CDC5 $131,455,1156 countrywide—have occurred. 9,792 $1,046,397,610 Number of EVD-Related USG ASSISTANCE TO THE WEST AFRICA 7 Deaths* EVD OUTBREAK RESPONSE WHO – March 4, 2015 KEY DEVELOPMENTS 11,466 As of March 3, the Government of Liberia (GoL) Incident Management System (IMS) had Number of EVD Cases in not reported a confirmed case of EVD in 12 days, with the most recent case documented in Sierra Leone* Montserrado County on February 19. On February 27, the IMS announced that Liberia had WHO – March 4, 2015 entered Phase 3 of the EVD response, which will focus on restoring non-EVD health services and improving triage and referral processes to enable medical staff to safely identify and isolate suspect EVD cases.
    [Show full text]
  • Interim Report Government of Japan COUNTERING EPIDEMIC-PRONE
    Government of Japan COUNTERING EPIDEMIC-PRONE DISEASES ALONG BORDERS AND MIGRATION ROUTE IN GUINEA Interim Report Project Period: 30 March 2016 – 29 March 2017 Reporting Period: 30 March 2016-31 August 2016 Funds: 2.000.000 USD Executing Organization: International Organization for Migration (IOM) Guinea October 2016 Interim Report to Government of Japan COUNTERING EPIDEMIC-PRONE DISEASES ALONG BORDERS AND MIGRATION ROUTES IN GUINEA Project Data Table Executing Organization: International Organization for Migration (IOM) Project Identification and IOM Project Code: MP.0281 Contract Numbers: Contract number: NI/IOM/120 Project Management Site Management Site: Conakry, CO, GUINEA and Relevant Regional Regional Office: Dakar, RO, SENEGAL Office: Project Period: 30 March 2016 – 29 March 2017 Geographical Coverage: Guinea Communal / Sub Prefectural / Prefectural / Regional Health authorities and Project Beneficiaries: Community members in Guinea Ministry of Health, National Health Security Agency, US Agency for international development (USAID), U.S. Office of Foreign Disaster Assistance Project Partner(s): (OFDA), Centre for Disease Control and Prevention (CDC), World Health Organization (WHO), International Medical Corps (IMC), Research triangle institute (RTI), Premieres Urgences (PU) Reporting Period: 30 March 2016 – 31 August 2017 Date of Submission: 30 October 2016 Total Confirmed 2,000,000 USD Funding: Total Funds Received to 2,000,000 USD Date: Total Expenditures: 439,761 USD Headquarters 17 route des Morillons • C.P. 71 • CH-1211
    [Show full text]